Author

M. Duong

Observed names: M.T. Duong, Michael Duong

Institution: Roche (Canada)

Observed institution: Roche (Canada)

ORCID: 0009-0008-5457-1024

Observed ORCID: 0009-0008-5457-1024

OpenAlex ID: A5087706118

The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada

2016 · M. Duong, E. Wright, et al. · Current Oncology · 13

Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis

2014 · Heather Cameron, Melissa Thompson, et al. · Blood · 3

Survival crossover adjustment and cost effectiveness analysis: An empirical and methodological review with application

2014 · R.B. Hopkins, K. Campbell, et al. · Value in Health · 1

Tocilizumab Monotherapy in Patients Where Methotrexate Is Considered Inappropriate: a Canadian Cost-utility Analysis

2016 · J. Marino, A. Diamantopoulos, et al. · Value in Health

Potential Long-Term Cost Savings Due to Significant Clinical Benefit of Obinutuzumab (Ga101) in Combination with Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia

2013 · S. Walzer, C. Tournier, et al. · Value in Health

Analysis of Transparency Amongst International Health Technology Assessment Organizations

2013 · F. Jebrail, M. Duong, et al. · Value in Health

PCN154 Challenges Posed by Patient Crossover for Cost-Effectiveness Analysis of Oncology Products: A Case Study in Metastatic Pancreatic Cancer

2012 · D.T. Grima, S.T. Brown, et al. · Value in Health

Works count: 7

Citation count: 17

H-index: 2

I10-index: 1